{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:00Z","timestamp":1787041680184,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119137","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:06:44Z","timestamp":1783627604000},"page":"119137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of an oral, potent and highly selective immunoproteasome inhibitor for the treatment of rheumatoid arthritis and ulcerative colitis"],"prefix":"10.1016","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8895-2087","authenticated-orcid":false,"given":"Xinran","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PengFei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8083-1984","authenticated-orcid":false,"given":"Xueyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runwei","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119137_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-biochem-060410-150257","article-title":"Molecular architecture and assembly of the eukaryotic proteasome","volume":"82","author":"Tomko","year":"2013","journal-title":"Annu. Rev. Biochem."},{"issue":"6624","key":"10.1016\/j.ejmech.2026.119137_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"issue":"5829","key":"10.1016\/j.ejmech.2026.119137_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8+ T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119137_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2011.05.004","article-title":"Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification and HLA-DR","volume":"37","author":"Fu","year":"2011","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119137_bib5","doi-asserted-by":"crossref","first-page":"39365","DOI":"10.31083\/FBL39365","article-title":"Macrophages in lupus nephritis: insights into its pathogenesis and emerging treatments","volume":"30","author":"Zhang","year":"2025","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119137_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"25","key":"10.1016\/j.ejmech.2026.119137_bib7","doi-asserted-by":"crossref","first-page":"131262","DOI":"10.1016\/j.tet.2020.131262","article-title":"Ganesh routholla, giri teja illa, D srinivasa reddy. Synthesis of \u03b1-ketoamides using potassium superoxide (KO2) as an oxidizing agent","volume":"76","author":"Vasudevan","year":"2020","journal-title":"Tetrahedron"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119137_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2174\/0929867323666160318173706","article-title":"Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases","volume":"23","author":"Ettari","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119137_bib9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119137_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.ejmech.2026.119137_bib11","doi-asserted-by":"crossref","first-page":"117790","DOI":"10.1016\/j.bmc.2024.117790","article-title":"Optimization of \u03b1-amido boronic acids via cryo-electron microscopy analysis: discovery of a novel highly selective immunoproteasome subunit LMP7 (\u03b25i)\/LMP2 (\u03b21i) dual inhibitor","volume":"109","author":"Arai","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119137_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41435-020-00109-1","article-title":"Recent insights how combined inhibition of immuno\/proteasome subunits enables therapeutic efficacy","volume":"21","author":"Basler","year":"2020","journal-title":"Gene Immun."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119137_bib13","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119137_bib14","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119137_bib15","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119137_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119137_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuroscience.2022.10.021","article-title":"PR-957 suppresses Th1 and Th17 cell differentiation via inactivating PI3K\/AKT pathway in alzheimer's disease","volume":"510","author":"Li","year":"2023","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119137_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1556\/1886.2017.00025","article-title":"Low neurotoxicity of ONX-0914 supports the idea of specific immunoproteasome inhibition as a side-effect-limiting, therapeutic strategy","volume":"7","author":"von Brzezinski","year":"2017","journal-title":"Eur J Microbiol Immunol (Bp)"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119137_bib19","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846512","article-title":"Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity","volume":"19","author":"Basler","year":"2018","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119137_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acsmedchemlett.6b00496","article-title":"Discovery of highly selective inhibitors of the immunoproteasome low molecular mass polypeptide 2 (LMP2) subunit","volume":"8","author":"B Johnson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119137_bib21","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"B Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119137_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-eular.3344","article-title":"AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers","volume":"77","author":"Lickliter","year":"2018","journal-title":"Ann. Rheum. Dis."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:04:46Z","timestamp":1787040286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"alternative-id":["S0223523426005829"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119137","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of an oral, potent and highly selective immunoproteasome inhibitor for the treatment of rheumatoid arthritis and ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119137"}}